FDA Adds New Side Effect to Ozempic Label
The FDA has updated Ozempic's label to include ileus as a serious side effect, highlighting growing concerns over gastrointestinal risks for users.
Ozempic (semaglutide), a widely prescribed medication for type 2 diabetes and increasingly used off-label for weight loss, now carries an updated FDA warning label highlighting ileus as a serious adverse reaction. This change, implemented in September 2023, stems from post-marketing reports of patients experiencing this potentially life-threatening gastrointestinal condition.Ileus involves a paralysis of intestinal muscles, preventing normal movement of food and waste, which can lead to severe complications like infection and tissue death.
What Is Ileus, and Why Was It Added to Ozempic’s Label?
Ileus is a rare but severe bowel obstruction where the intestines fail to contract properly, causing a blockage. Symptoms include abdominal bloating, cramps, constipation, nausea, vomiting, and in severe cases, bowel perforation or death. The FDA added ileus to Ozempic’s prescribing information under ‘postmarketing experience’ based on voluntary patient reports after the drug’s approval.
While no direct causal link has been definitively established, the FDA requires label updates for emerging safety signals. Approximately 20 cases, including two fatalities, were linked to Ozempic use by late 2023, prompting the change. This warning also applies to Wegovy, Ozempic’s sister drug for weight loss, produced by Novo Nordisk.
History of Ozempic: From Approval to Growing Concerns
Novo Nordisk’s Ozempic received initial FDA approval on December 5, 2017, for glycemic control in adults with type 2 diabetes. In January 2020, approval expanded to reduce cardiovascular risks like heart attacks and strokes in patients with established heart disease.
Its popularity surged due to significant weight loss effects—up to 15-20% body weight reduction in trials—leading to off-label prescriptions amid shortages for diabetes patients. However, gastrointestinal side effects like nausea, vomiting, diarrhea, and abdominal pain are common, affecting over 20% of users in clinical studies.
- Key Milestones:
- 2017: Approved for type 2 diabetes management.
- 2020: Added cardiovascular risk reduction indication.
- 2023: Label updated for ileus warning.
- Recent: Anesthesia risk and vision concerns investigated.
Symptoms and Risks of Gastrointestinal Side Effects
GLP-1 receptor agonists like Ozempic slow gastric emptying to regulate blood sugar, but this mechanism heightens GI risks. Common issues include gastroparesis (stomach paralysis), now joined by ileus warnings.
| Side Effect | Symptoms | Severity |
|---|---|---|
| Gastroparesis | Nausea, vomiting undigested food, bloating, abdominal pain | Moderate to Severe |
| Ileus | Constipation, cramps, vomiting, bloating, no bowel sounds | Life-Threatening |
| Other GI | Diarrhea, nausea | Mild-Moderate |
Patients should seek immediate care for persistent vomiting or severe pain. Risk factors include higher doses, dehydration, or prior abdominal surgery.
Recent FDA Label Updates Beyond Ileus
In addition to the September 2023 ileus addition, the FDA issued warnings about anesthesia risks. Ozempic users face heightened pulmonary aspiration during procedures under general anesthesia or deep sedation due to delayed gastric emptying. Standard fasting may not suffice, though specific mitigation guidelines are lacking.
Counterfeit Ozempic concerns peaked in 2023-2025, with FDA seizures of fake pens risking infection from non-sterile needles. Patients must verify lot numbers like PAR0362 or NAR0074 and obtain via licensed pharmacies.
Lawsuits and Legal Actions Surrounding Ozempic
Over 1,200 lawsuits consolidated in multidistrict litigation by late 2024 allege Novo Nordisk failed to warn of gastroparesis, ileus, and blockages. Plaintiffs report permanent stomach damage requiring feeding tubes or surgeries.
- Claims: Inadequate warnings on GI paralysis risks.
- Defenses: Side effects listed; benefits outweigh risks for approved uses.
- Status: Ongoing, with settlements possible as evidence mounts.
Other Emerging Health Concerns
A JAMA Ophthalmology study linked semaglutide to nonarteritic anterior ischemic optic neuropathy (NAION), a vision loss condition from reduced eye blood flow. Investigations into lawsuits are underway.
Vision changes, thyroid tumors (from rodent studies), and pancreatitis remain in warnings. The label emphasizes reporting via FDA MedWatch.
What Should Ozempic Users Do?
Consult healthcare providers before stopping; abrupt discontinuation risks blood sugar spikes. Discuss risks if planning surgery, and hold doses pre-procedure per anesthesia guidelines.
- Monitor for severe GI symptoms.
- Use only prescribed, authentic product.
- Report adverse events to FDA.
- Explore alternatives like Mounjaro for dual GIP/GLP-1 action.
Expert Insights on Ozempic’s Risk-Benefit Profile
For type 2 diabetes, Ozempic reduces A1C by 1-2% and cardiovascular events by 26% in trials. Weight loss benefits aid obesity-related conditions, but off-label use amplifies risks without full oversight.
Experts recommend lowest effective doses, hydration, and gradual titration to minimize GI issues. Long-term data is evolving as use expands.
Frequently Asked Questions (FAQs)
What is the new FDA warning for Ozempic?
The label now includes ileus, an intestinal blockage causing severe GI issues, based on post-approval reports. It applies to Wegovy too.
When was ileus added to the Ozempic label?
September 2023, under postmarketing experience.
Can Ozempic cause gastroparesis?
Lawsuits claim yes, with stomach paralysis symptoms; FDA monitors but hasn’t added it yet.
Is Ozempic safe for weight loss?
Approved for diabetes; off-label for weight loss carries similar risks. Wegovy is preferred for obesity.
What are signs of ileus?
Bloating, severe pain, vomiting, constipation—seek emergency care.
How to avoid counterfeit Ozempic?
Fill prescriptions at licensed pharmacies; check lot/serial numbers.
References
- Ozempic®: FDA Warning Label Information — Motley Rice. 2023-09. https://www.motleyrice.com/diabetes-lawsuits/ozempic/fda-warning
- FDA Updates Ozempic Label With Anesthesia Warning — Consumer Notice. 2024. https://www.consumernotice.org/news/fda-updates-ozempic-label-with-anesthesia-warning/
- FDA Updates Ozempic Label With Warning for Intestinal Blockages — diaTribe. 2023. https://diatribe.org/diabetes-medications/fda-updates-ozempic-label-warning-intestinal-blockages
- FDA warns consumers not to use counterfeit Ozempic — U.S. Food & Drug Administration. 2023-12-21. https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-consumers-not-use-counterfeit-ozempic-semaglutide-found-us-drug-supply-chain
- New FDA warning label for Ozempic and Wegovy — American Medical Association. 2023. https://www.ama-assn.org/public-health/infectious-diseases/new-fda-warning-label-ozempic-and-wegovy-plus-how-and-where-get
- OZEMPIC (semaglutide) Injection Label — U.S. Food & Drug Administration. 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209637s020s021lbl.pdf
Similar Articles
Read full bio of Sneha Tete
